1.Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology. 1996;24(2):451-9.
2.Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, et al. Cirrhotic cardiomyopathy. Journal of the American College of Cardiology. 2010;56(7):539-49.
3.Wong F. Cirrhotic cardiomyopathy. Hepatol Int. 2009;3:294–304.
4.Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Centers for Disease Control and Prevention website www cdcgov/nchs/data/nvsr/nvsr61/nvsr61_04pdf 2014.
5.Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. Journal of hepatology. 2013;58(3):593-608.
6.Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. . Hepatology American Association for the Study of Liver Diseases website. 2014(
www.aasld. org/practiceguidelines/Documents/Bookmarked% 20Practice % 20Guidelines/Chronic_Hep_B_Update_2009%20 8_24_2009.pdf. ).
7.Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6):1293-302 e4.
8.Fede G, D'Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. Journal of hepatology. 2012;56(4):810-8.
9.Brodehl A, Hedde PN, Dieding M, Fatima A, Walhorn V, Gayda S, et al. Dual color photoactivation localization microscopy of cardiomyopathy-associated desmin mutants. The Journal of biological chemistry. 2012;287(19):16047-57.
10.Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut. 2008;57(2):268-78
11.Moller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Digestive diseases and sciences. 2015;60(11):3209-25.
12.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014;8(3):308-15.
13.Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. Journal of the American College of Cardiology. 2004;44(6):1164-71.
14.Pall A, Czifra A, Vitalis Z, Papp M, Paragh G, Szabo Z. Pathophysiological and clinical approach to cirrhotic cardiomyopathy. Journal of gastrointestinal and liver diseases : JGLD. 2014;23(3):301-10.
15.Pozzi M, Grassi G, Ratti L, Favini G, Dell'Oro R, Redaelli E, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. The American journal of gastroenterology. 2005;100(5):1110-6.
16.Mota VGa, B F, Markman. . Echocardiography in Chronic Liver Disease: Systematic Review. . Arq Bras Cardiol, . 2013;100(4)::376-85.
17.Torregrosa M, Aguade S, Dos L, e ta, l. . Cardiac alterations in cirrhosis: reversibility after liver transplantation. Journal of hepatology. 2005;42:68-74.
18.Karagiannakis DS. Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis. . Hepatol Int 2014;8(4): :588-94. .
19.Dahl EK. Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study. . Scand J Gastroenterol 2014;49(3): :362-72. .
20.Serste T. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. . Journal of hepatology. 2011;55(4): :794-9.